A comparison study specifically focusing on different tigecycline generics could not be located within the provided sources. However, it is important to note that the FDA has issued a safety communication regarding the increased risk of death associated with Tygacil (tigecycline) compared to other antibiotics [3]. This communication highlights the need for caution when using tigecycline and the importance of considering alternative treatment options. Additionally, the FDA's communication emphasizes the importance of healthcare professionals and patients being aware of the risks associated with tigecycline use [3]. While the sources provided do not contain a direct study comparing tigecycline generics, they do offer valuable information regarding the safety concerns associated with tigecycline use.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591878/
[3] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics